Post-Pandemic Rise in New Pediatric Antidepressant Prescriptions Reached 35% Nationally, Led by Girls
National records show sustained elevation in new pediatric mental health treatment after schools reopened, exceeding pre-pandemic levels and concentrated in first-time antidepressant use among girls. This reflects acceleration of decade-long trends documented by CDC surveys rather than a transient pandemic effect. Evidence quality remains limited to observational claims data without clinical outcome measures.
Longitudinal outcome studies are now required to determine whether elevated prescription rates translate into sustained reductions in functional impairment or suicide attempts. Future national datasets should stratify by socioeconomic status and race to identify whether access disparities widened alongside overall treatment volume.
VITALIS: National antidepressant initiation rates for girls ages 6-12 will remain at least 80% above 2019 levels in 2025 claims data releases.
Sources (3)
- [1]Primary Source(https://www.jaacapopen.org/article/S2949-7329(24)00045-6)
- [2]Supporting Source(https://www.cdc.gov/yrbs/index.html)
- [3]Supporting Source(https://jamanetwork.com/journals/jamapediatrics/fullarticle/2801234)